<p>Oruka Therapeutics, Inc.（纳斯达克代码：ORKA - 获取免费报告）的股票在周二上涨了 5%，因为瑞银集团将该股票的目标价从 50.00 美元上调至 75.00 美元。瑞银集团目前对该股票给予买入评级。Oruka Therapeutics 的股价最高曾达到 58.53 美元，最后交易价为 59.20 美元。在交易过程中，约有 623,149 股成交，较平均每日成交量 584,512 股增加了 7%。该股票此前收盘价为 56.37 美元。</p>
<p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
<p>其他分析师最近也对该公司发布了报告。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Oruka Therapeutics 股票的 “卖出（d-）” 评级。巴克莱将 Oruka Therapeutics 的目标价从 48.00 美元上调至 50.00 美元，并在 3 月 13 日的研究报告中给予该公司 “增持” 评级。派珀·桑德勒在 12 月 18 日的研究报告中开始覆盖 Oruka Therapeutics。他们为该公司设定了 “增持” 评级和 75.00 美元的目标价。古根海姆在 3 月 13 日的研究报告中重申了 “买入” 评级，并为 Oruka Therapeutics 股票设定了 60.00 美元的目标价。最后，Leerink Partners 在 3 月 16 日的报告中将 Oruka Therapeutics 的目标价从 58.00 美元上调至 86.00 美元，并给予该股票 “跑赢大盘” 评级。十位研究分析师对该股票给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，Oruka Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 62.10 美元。</p>
<p><strong>查看我们关于 ORKA 的最新研究报告</strong></p>
<h2>Oruka Therapeutics 的内部买卖情况</h2>
<p>在其他 Oruka Therapeutics 的新闻中，首席执行官 Lawrence Otto Klein 在 3 月 16 日的交易中出售了 1,729 股该股票。该股票以平均价格 41.30 美元出售，总价值为 71,407.70 美元。出售完成后，首席执行官在公司中持有 927,309 股，价值约为 38,297,861.70 美元。这代表其持股比例下降了 0.19%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Joana Goncalves 在 3 月 16 日的交易中出售了 7,641 股公司的股票。该股票以平均价格 40.91 美元出售，总交易额为 312,593.31 美元。交易完成后，该内部人士直接持有 33,377 股公司股票，价值为 1,365,453.07 美元。这笔交易代表其持股比例下降了 18.63%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了价值 849,575 美元的 23,765 股公司股票。内部人士持有公司 24.69% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该公司的持股。Fairmount Funds Management LLC 在第三季度将其在 Oruka Therapeutics 的股份增加了 9.9%。Fairmount Funds Management LLC 现在持有该公司 3,705,262 股股票，价值 71,252,000 美元，此前在上个季度又购买了 333,340 股。Viking Global Investors LP 在第三季度购买了 Oruka Therapeutics 的新头寸，价值约为 51,280,000 美元。Deep Track Capital LP 在第三季度将其在 Oruka Therapeutics 的股份增加了 38.4%。Deep Track Capital LP 现在持有该公司 2,654,781 股股票，价值 51,051,000 美元，此前在上个季度又购买了 735,983 股。先锋集团在第四季度将其在 Oruka Therapeutics 的股份增加了 38.1%。先锋集团现在持有该公司 2,453,530 股股票，价值 74,366,000 美元，此前在上个季度又购买了 676,865 股。最后，RTW Investments LP 在第四季度将其在 Oruka Therapeutics 的股份增加了 5.8%。RTW Investments LP 现在持有该公司 2,058,148 股股票，价值 62,382,000 美元，此前在上个季度又购买了 112,499 股。对冲基金和其他机构投资者持有公司 56.44% 的股份。</p>
<h2>Oruka Therapeutics 股票表现</h2>
<p>该公司的 50 日移动平均价格为 37.40 美元，200 日移动平均价格为 31.02 美元。该股票的市值为 29.5 亿美元，市盈率为-31.99，贝塔值为-0.54。</p>
<p>Oruka Therapeutics（纳斯达克代码：ORKA - 获取免费报告）最近于 3 月 12 日发布了其财报。该公司报告每股收益（EPS）为-0.45 美元，超出市场共识预期的-0.61 美元，超出幅度为 0.16 美元。平均而言，股票研究分析师预测 Oruka Therapeutics, Inc.在当前年度的每股收益为-3.41 美元。</p>
<h2>Oruka Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发新型基于肽的肿瘤治疗。该公司的专有固定肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过结合生物制剂的特异性与小分子的细胞渗透性，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
<p>该公司的主要候选药物 ONCT-01 目前正在进行针对晚期实体瘤患者的第一阶段临床试验，评估其安全性、耐受性和初步疗效。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Oruka Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Oruka Therapeutics 吗？</h2>
<p>在你考虑投资 Oruka Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oruka Therapeutics 并不在名单上。</p>
<p>虽然 Oruka Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普全球医疗股指数 ETF - iShares

IBBQ

标普生物技术 3 倍做多 - Direxion

<p>Oruka Therapeutics (NASDAQ:ORKA) 的股价上涨了 5%，因为瑞银集团将其目标价从 50 美元上调至 75 美元，并维持买入评级。该股票交易价格为 59.20 美元，成交量增加了 7%。分析师的评级不一，十位分析师推荐买入，一位分析师建议卖出。内部人士最近出售了股票，机构投资者持有该股票的 56.44%。该公司报告的季度每股收益为 -0.45 美元，超出预期。Oruka 专注于开发基于肽的肿瘤治疗药物</p>

<p>Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) were up 5% on Tuesday after UBS Group raised their price target on the stock from $50.00 to $75.00. UBS Group currently has a buy rating on the stock. Oruka Therapeutics traded as high as $58.53 and last traded at $59.20. Approximately 623,149 shares changed hands during trading, an increase of 7% from the average daily volume of 584,512 shares. The stock had previously closed at $56.37.</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc.（纳斯达克代码：ORKA - 获取免费报告）的股票在周二上涨了 5%，因为瑞银集团将该股票的目标价从 50.00 美元上调至 75.00 美元。瑞银集团目前对该股票给予买入评级。Oruka Therapeutics 的股价最高曾达到 58.53 美元，最后交易价为 59.20 美元。在交易过程中，约有 623,149 股成交，较平均每日成交量 584,512 股增加了 7%。该股票此前收盘价为 56.37 美元。</p>
</div><p>Get <strong>Oruka Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
</div><p>Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Barclays lifted their price objective on Oruka Therapeutics from $48.00 to $50.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, March 13th. Piper Sandler started coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They set an &#34;overweight&#34; rating and a $75.00 price objective for the company. Guggenheim restated a &#34;buy&#34; rating and set a $60.00 price target on shares of Oruka Therapeutics in a research report on Friday, March 13th. Finally, Leerink Partners lifted their price objective on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, March 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $62.10.</p>
<div class="lb-trans"><p>其他分析师最近也对该公司发布了报告。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Oruka Therapeutics 股票的 “卖出（d-）” 评级。巴克莱将 Oruka Therapeutics 的目标价从 48.00 美元上调至 50.00 美元，并在 3 月 13 日的研究报告中给予该公司 “增持” 评级。派珀·桑德勒在 12 月 18 日的研究报告中开始覆盖 Oruka Therapeutics。他们为该公司设定了 “增持” 评级和 75.00 美元的目标价。古根海姆在 3 月 13 日的研究报告中重申了 “买入” 评级，并为 Oruka Therapeutics 股票设定了 60.00 美元的目标价。最后，Leerink Partners 在 3 月 16 日的报告中将 Oruka Therapeutics 的目标价从 58.00 美元上调至 86.00 美元，并给予该股票 “跑赢大盘” 评级。十位研究分析师对该股票给予了买入评级，一位分析师对该公司给予了卖出评级。根据 MarketBeat 的数据，Oruka Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 62.10 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ORKA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ORKA 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling at Oruka Therapeutics</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 的内部买卖情况</h2>
</div><p>In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the business's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 23,765 shares of company stock worth $849,575 over the last three months. Insiders own 24.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Oruka Therapeutics 的新闻中，首席执行官 Lawrence Otto Klein 在 3 月 16 日的交易中出售了 1,729 股该股票。该股票以平均价格 41.30 美元出售，总价值为 71,407.70 美元。出售完成后，首席执行官在公司中持有 927,309 股，价值约为 38,297,861.70 美元。这代表其持股比例下降了 0.19%。该出售在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Joana Goncalves 在 3 月 16 日的交易中出售了 7,641 股公司的股票。该股票以平均价格 40.91 美元出售，总交易额为 312,593.31 美元。交易完成后，该内部人士直接持有 33,377 股公司股票，价值为 1,365,453.07 美元。这笔交易代表其持股比例下降了 18.63%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了价值 849,575 美元的 23,765 股公司股票。内部人士持有公司 24.69% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the business. Fairmount Funds Management LLC raised its stake in Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company's stock worth $71,252,000 after buying an additional 333,340 shares in the last quarter. Viking Global Investors LP bought a new position in Oruka Therapeutics in the third quarter worth approximately $51,280,000. Deep Track Capital LP raised its stake in Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after buying an additional 735,983 shares in the last quarter. Vanguard Group Inc. raised its stake in Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock worth $74,366,000 after buying an additional 676,865 shares in the last quarter. Finally, RTW Investments LP raised its stake in Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after buying an additional 112,499 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Fairmount Funds Management LLC 在第三季度将其在 Oruka Therapeutics 的股份增加了 9.9%。Fairmount Funds Management LLC 现在持有该公司 3,705,262 股股票，价值 71,252,000 美元，此前在上个季度又购买了 333,340 股。Viking Global Investors LP 在第三季度购买了 Oruka Therapeutics 的新头寸，价值约为 51,280,000 美元。Deep Track Capital LP 在第三季度将其在 Oruka Therapeutics 的股份增加了 38.4%。Deep Track Capital LP 现在持有该公司 2,654,781 股股票，价值 51,051,000 美元，此前在上个季度又购买了 735,983 股。先锋集团在第四季度将其在 Oruka Therapeutics 的股份增加了 38.1%。先锋集团现在持有该公司 2,453,530 股股票，价值 74,366,000 美元，此前在上个季度又购买了 676,865 股。最后，RTW Investments LP 在第四季度将其在 Oruka Therapeutics 的股份增加了 5.8%。RTW Investments LP 现在持有该公司 2,058,148 股股票，价值 62,382,000 美元，此前在上个季度又购买了 112,499 股。对冲基金和其他机构投资者持有公司 56.44% 的股份。</p>
</div><h2>Oruka Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 股票表现</h2>
</div><p>The firm has a fifty day moving average price of $37.40 and a 200 day moving average price of $31.02. The stock has a market cap of $2.95 billion, a PE ratio of -31.99 and a beta of -0.54.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 37.40 美元，200 日移动平均价格为 31.02 美元。该股票的市值为 29.5 亿美元，市盈率为-31.99，贝塔值为-0.54。</p>
</div><p>Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Oruka Therapeutics（纳斯达克代码：ORKA - 获取免费报告）最近于 3 月 12 日发布了其财报。该公司报告每股收益（EPS）为-0.45 美元，超出市场共识预期的-0.61 美元，超出幅度为 0.16 美元。平均而言，股票研究分析师预测 Oruka Therapeutics, Inc.在当前年度的每股收益为-3.41 美元。</p>
</div><h2>Oruka Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发新型基于肽的肿瘤治疗。该公司的专有固定肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过结合生物制剂的特异性与小分子的细胞渗透性，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
</div><p>The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.</p>
<div class="lb-trans"><p>该公司的主要候选药物 ONCT-01 目前正在进行针对晚期实体瘤患者的第一阶段临床试验，评估其安全性、耐受性和初步疗效。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Oruka Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Oruka Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oruka Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oruka Therapeutics 吗？</h2>
</div><p>Before you consider Oruka Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Oruka Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Oruka Therapeutics 并不在名单上。</p>
</div><p>While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oruka Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oruka Therapeutics (NASDAQ:ORKA) 在分析师上调评级后股价上涨 5%